- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Navigating New Frontiers: Bruton Tyrosine Kinase Inhibitors in Chronic Spontaneous Urticaria Treatment
In this discussion, panelists explore the potential role of new Bruton tyrosine kinase inhibitors in the treatment landscape for chronic spontaneous urticaria (CSU), evaluating their stages of development and expected impact on treatment algorithms, while also considering future changes in coverage and payer strategies with the emergence of new therapies.
EP: 1.The Pathophysiology of Chronic Spontaneous Urticaria
EP: 2.Hallmark Symptoms of Chronic Spontaneous Urticaria
EP: 3.The Epidemiology Associated With Chronic Spontaneous Urticaria
EP: 4.Differential Diagnosis When Considering Chronic Spontaneous Urticaria
EP: 5.Healthcare Specialties Involved in Managing Patients With Chronic Spontaneous Urticaria
EP: 6.Therapies Typically Used in the Firstline For Patients With Chronic Spontaneous Urticaria
EP: 7.Approaches to Switching Between Antihistamines and Other Medications When Treating Patients with Chronic Spontaneous Urticaria
EP: 8.The Use of Systemic Corticosteroids In Chronic Spontaneous Urticaria Treatment
EP: 9.Addressing Persistent Symptoms in Chronic Spontaneous Urticaria: Beyond IgE-Targeted Treatments
EP: 10.Key Updates Needed in Chronic Spontaneous Urticaria Guidelines
EP: 11.The Evaluation of Dupilumab In Chronic Spontaneous Urticaria Treatment
EP: 12.Navigating New Frontiers: Bruton Tyrosine Kinase Inhibitors in Chronic Spontaneous Urticaria Treatment
EP: 13.Patient Education, Provider Education, and Overall Final Thoughts
Video content above is prompted by the following question:
- Where do you see certain prescriptions fitting into treatment algorithms for patients living with chronic spontaneous urticaria (CSU)?
a. Given the data you’ve seen to date, how would you advise managed
- Another Bruton tyrosine kinase inhibitor, rilzabrutinib, is also under investigation for patients living with CSU. What stage of development is this molecule in and what has the data demonstrated?
- How do you see treatment algorithms changing in the future with the introduction of newer classes of therapies?
a. With potential new treatment options on the horizon, how do you think payers should anticipate covering CSU in the next few years?
Hidradenitis Suppurativa Disproportionately Affects Black, Female Patients
September 25th 2024A poster presented at the Skin of Color Update reported that hidradenitis suppurativa (HS) disproportionately affects Black patients, women, smokers, and those with public insurance or disabilities.
Read More
Dermatologist Dissects Rosacea Diagnosis Challenges Among Patients of Color
September 17th 2024Hilary Baldwin, MD, FAAD, highlighted diagnostic complexities and shared treatment strategies for rosacea in patients with darker skin tones at the Skin of Color Update in New York City last Friday.
Read More
Expert Highlights Need for Greater Diversity in Dermatology Clinical Trials
September 17th 2024Valerie M. Harvey, MD, MPH, FAAD, founder of the Hampton Roads Center for Dermatology, highlighted the long-standing underrepresentation of minority populations in dermatology clinical trials at the Skin of Color Update 2024 in New York City on Friday.
Read More
FDA Approves Lebrikizumab For Patients Aged 12 and Older With Moderate to Severe Atopic Dermatitis
September 16th 2024The FDA has approved lebrikizumab (Ebglyss; Eli Lilly) as a new first-line biologic treatment for patients aged 12 and older with moderate to severe atopic dermatitis (AD).
Read More
